Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Introduction: Alzheimer’s disease (AD) is increasing in frequency as the global population ages. Five drugs are approved for treatment of AD, including four cholinesterase inhibitors and an N -methyl-D-aspartate (NMDA)-receptor antagonist. We have an urgent need to find new therapies for AD. Methods: We examined Clinicaltrials.gov, a public website that records ongoing clinical trials. We examined the decade of 2002 to 2012, to better understand AD-drug development. We reviewed trials by sponsor, sites, drug mechanism of action, duration, number of patients required, and rate of success in terms of advancement from one phase to the next. We also reviewed the current AD therapy pipeline. Results: During the 2002 to 2012 observation period, 413 AD trials were performed: 124 Phase 1 trials, 206 Phase 2 trials, and 83 Phase 3 trials. Seventy-eight percent were sponsored by pharmaceutical companies. The United States of America (U.S.) remains the single world region with the greatest number of trials; cumulatively, more non-U.S. than U.S. trials are performed. The largest number of registered trials addressed symptomatic agents aimed at improving cognition (36.6%), followed by trials of disease-modifying small molecules (35.1%) and trials of disease-modifying immunotherapies (18%). The mean length of trials increases from Phase 2 to Phase 3, and the number of participants in trials increases between Phase 2 and Phase 3. Trials of disease-modifying agents are larger and longer than those for symptomatic agents. A very high attrition rate was found, with an overall success rate during the 2002 to 2012 period of 0.4% (99.6% failure). Conclusions: The Clinicaltrials.gov database demonstrates that relatively few clinical trials are undertaken for AD therapeutics, considering the magnitude of the problem. The success rate for advancing from one phase to another is low, and the number of compounds progressing to regulatory review is among the lowest found in any therapeutic area. The AD drug-development ecosystem requires support.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the very high failure rate of clinical trials of AD therapeutics (of ~99.6%), many of which were successful in preclinical testing using these animal models [6, 27, 139]”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“New AD drug development has faced many obstacles, including high monetary and time costs and high failure rates in preclinical and clinical trials (Cummings et al., 2014;Yiannopoulou et al., 2019).”
From Drug repurposing for Alzheimer’s disease from 2012–2022—a 10-year literature review (2023) · cites this paper as Cummings et al., 2014
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Currently approved drugs do little to limit disease progression, and no preventive therapies are available.3,4”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“the success rate of drugs that have gone through clinical trials from 2002 to 2012 show a high failure rate (~ 99.6%) [69]”
From Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function (2022) · cites this paper as [69]
The cited source says what the claim attributes to it.
In the citing paper
“Efforts to develop drugs to treat Alzheimer’s dementia (AD) have a >99% failure rate”
From Exposure to Air Pollution in Relation to Risk of Dementia and Related Outcomes: An Updated Systematic Review of the Epidemiological Literature (2021) · cites this paper as Cummings et al. 2014
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“This is among the lowest for any therapeutic area [13,14].”
Background2013 Alzheimer's disease facts and figures
Alzheimer's Association, Thies, W., & Bleiler, L. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.02.003 · Cited by 3,328
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536 · cited 1×
“This is among the lowest for any therapeutic area [13,14].”
BackgroundThe International Committee of Medical Journal Editors
van der Weyden, M. (2006) · Proceedings of the Workshop on Publishing for Biomedical Journal Editors and Reviewers · doi:10.2349/biij.2.4.e54-13 · Cited by 1,998
Monetary Costs of Dementia in the United States
Hurd, M. D., Martorell, P., Delavande, A., Mullen, K. J., & Langa, K. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1204629 · Cited by 1,484 · cited 1×
“economy than cardiovascular disease or cancer [31].”
2012 Alzheimer's disease facts and figures Alzheimer's Association ∗
Thies, W., & Bleiler, L. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.02.001 · Cited by 982
Donepezil and memantine for moderate-to-severe Alzheimer's disease
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106668 · Cited by 782 · cited 1×
“2014 receptor AD antagonist (memantine) [3,4].”
Alzheimer's Disease and the Amyloid Cascade Hypothesis: A Critical Review
Reitz, C. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/369808 · Cited by 376 · cited 1×
“neurobiology of AD, and use of combinations of therapies may provide new approaches to AD therapy [24-26].”
BackgroundMullane, K., & Williams, M. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.11.014 · Cited by 213 · cited 1×
“Many failures in AD drug development have occurred, with both small molecules and immunotherapies failing to show a drug/placebo difference or having unacceptable toxicity [5-8].”
Background
Research works printed but not linked: 4
- Food and Drug Administration: Guidance for Industry: Information Program on Clinical Trials for Serious or Life-threatening Disease and Conditions. 2002, Bethesda, MD: US Department of Health and Human Services, Food and Drug Administration
- Food and Drug Administration: Guidance for Industry: Information Program on Clinical Trials for Serious or Life-threatening Disease and Conditions. 2004, Bethesda: US Department of Health and Human Services, Food and Drug Administration
- Getz K, Lamberti MJ: 89% of trials meet enrollment, but timelines slip, half of sites under-enroll. Tufts Cent Study Drug Dev. 2013, 15: 1-4.
- DiMasi JA: Clinical success rates for new cancer drugs double while more enter testing. Tufts Center Study Drug Dev Impact Rep. 2013, 15: 1-4.
Cited by
Nichols, E., Steinmetz, J. D., Vollset, S. E., Fukutaki, K., Chalek, J., Abd-Allah, F., Abdoli, A., Abualhasan, A., Abu-Gharbieh, E., Akram, T. T., et al. (2022) · The Lancet Public Health · doi:10.1016/s2468-2667(21)00249-8 · Cited by 5,575
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
“gov, a National Institutes of Health registry of publicly and privately funded clinical studies [106].”
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Nichols, E., Szoeke, C. E. I., Vollset, S. E., Abbasi, N., Abd-Allah, F., Abdela, J., Aichour, M. T. E., Akinyemi, R. O., Alahdab, F., Asgedom, S. W., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30403-4 · Cited by 2,412
2018 Alzheimer's disease facts and figures
Alzheimer's Association (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.001 · Cited by 1,912
“gov, a National Institutes of Health registry of publicly and privately funded clinical studies [133].”
2015 Alzheimer's disease facts and figures
Alzheimer's Association (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.02.003 · Cited by 1,635
2017 Alzheimer's disease facts and figures
(2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.02.001 · Cited by 1,311
“gov, a National Institutes of Health registry of publicly and privately funded clinical studies [124].”
Religious Orders Study and Rush Memory and Aging Project
Bennett, D. A., Buchman, A. S., Boyle, P. A., Barnes, L. L., Wilson, R. S., & Schneider, J. A. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179939 · Cited by 1,260
“The string of failed studies is long despite the investment of billions of dollars from the public and private sectors, the participation of many tens of thousands of people in clinical trials, and the efforts of thousands of researchers and study staff [440].”
Dyall, S. C. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00052 · Cited by 943
“Furthermore, a recent meta-analysis has shown that relatively few clinical trials are being undertaken for AD therapeutics, and the number of compounds progressing to regulatory review is among the lowest found in any therapeutic area (Cummings et al., 2014), highlighting the importance of developing new therapeutic a…”
BackgroundGlobal estimates on the number of persons across the Alzheimer's disease continuum
Gustavsson, A., Norton, N., Fast, T., Frölich, L., Georges, J., Holzapfel, D., Kirabali, T., Krolak‐Salmon, P., Rossini, P. M., Ferretti, M. T., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12694 · Cited by 895
The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade
Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179941 · Cited by 870
Zheng, J., Haberland, V., Baird, D., Walker, V., Haycock, P., Hurle, M., Gutteridge, A., Erola, P., Liu, Y., Luo, S., et al. (2019) · doi:10.1101/627398 · Cited by 812
Alzheimer's disease: experimental models and reality
Drummond, E., & Wisniewski, T. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1662-x · Cited by 810
“6%), many of which were successful in preclinical testing using these animal models [6, 27, 139].”
Background(2019) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-804766-8.00013-3 · Cited by 783
Alzheimer's disease drug development pipeline: 2018
Cummings, J., Lee, G., Ritter, A., & Zhong, K. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.03.009 · Cited by 697
Self-citationDrug discovery and development: Role of basic biological research
Mohs, R. C., & Greig, N. H. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.10.005 · Cited by 673
“Most (78%) of the 413 clinical trials (244 unique molecules) conducted of potential medicines for AD between 2002 and 2012 were supported by the pharmaceutical industry [4].”
BackgroundInfluentialAlzheimer’s Disease: Past, Present, and Future
Bondi, M. W., Edmonds, E. C., & Salmon, D. P. (2017) · Journal of the International Neuropsychological Society · doi:10.1017/s135561771700100x · Cited by 649
Applications of machine learning to diagnosis and treatment of neurodegenerative diseases
Myszczynska, M. A., Ojamies, P. N., Lacoste, A. M. B., Neil, D., Saffari, A., Mead, R., Hautbergue, G. M., Holbrook, J. D., & Ferraiuolo, L. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0377-8 · Cited by 595
Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options
Cummings, J. L., Tong, G., & Ballard, C. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-180766 · Cited by 588
“Despite the growing population of patients with AD, only five treatment options are currently approved to treat the cognitive symptoms of AD in the United States, the most recent of which (memantine) was approved more than a decade ago [10].”
BackgroundSelf-citationDrug treatments in Alzheimer’s disease
Briggs, R., Kennelly, S. P., & O’Neill, D. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-3-247 · Cited by 571
Alzheimer's disease drug development pipeline: 2017
Cummings, J., Lee, G., Mortsdorf, T., Ritter, A., & Zhong, K. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.05.002 · Cited by 549
“Although there are promising agents in the pipeline that could achieve this goal, it is clear that given the high rate of failure of AD drug development [38], the aim of having a repertoire of agents that could respond comprehensively and individually to a patient’s clinical circumstances within the 2025 timeframe is…”
BackgroundSelf-citationState of the science on mild cognitive impairment (MCI)
Anderson, N. D. (2019) · CNS Spectrums · doi:10.1017/s1092852918001347 · Cited by 541
“The clinical criteria for mild NCD include: (1) evidence of cognitive decline in one or more cognitive domains, obtained from reports from the client, an informant, or a clinician, or from objective testing; (2) preserved functional independence; (3) the cognitive impairments do not occur exclusively during episodes o…”
InfluentialThe promise of organ and tissue preservation to transform medicine
Giwa, S., Lewis, J. K., Alvarez, L., Langer, R., Roth, A. E., Church, G. M., Markmann, J. F., Sachs, D. H., Chandraker, A., Wertheim, J. A., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.3889 · Cited by 539
Microbes and Alzheimer’s Disease
Itzhaki, R. F., Lathe, R., Balin, B. J., Ball, M. J., Bearer, E. L., Braak, H., Bullido, M. J., Carter, C., Clerici, M., Cosby, S. L., et al. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160152 · Cited by 532
“Given the failure of the 413 trials of other types of therapy for AD carried out in the period 2002–2012 [79], antiviral/antimicrobial treatment of AD patients, notably those who are APOE 4 carriers, could rectify the ‘no drug works’ impasse.”
Mostafavi, S., Gaiteri, C., Sullivan, S. E., White, C. C., Tasaki, S., Xu, J., Taga, M., Klein, H.-U., Patrick, E., Komashko, V., et al. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0154-9 · Cited by 509
“The incidence of late-onset Alzheimer’s disease (AD) is expected to triple by 2050 1 , yet no therapies are available to treat or prevent the disease 2 .”
Drug development in Alzheimer’s disease: the path to 2025
Cummings, J., Aisen, P. S., DuBois, B., Frölich, L., Jack, C. R., Jones, R. W., Morris, J. C., Raskin, J., Dowsett, S. A., & Scheltens, P. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0207-9 · Cited by 459
“Despite the evaluation of numerous potential treatments in clinical trials [4, 5], only four cholinesterase in-”
BackgroundSelf-citationThe antimicrobial protection hypothesis of Alzheimer’s disease
Moir, R. D., Lathe, R., & Tanzi, R. E. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.06.3040 · Cited by 456
“Hundreds of clinical trials have been conducted to test AD treatments, with Ab being the most frequent pharmacological target [97].”
Therapeutic strategies for Alzheimer's disease in clinical trials
Godyń, J., Jończyk, J., Panek, D., & Malawska, B. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2015.07.006 · Cited by 452
“gov data), 83 phase III trials were performed between 2001 and 2012 [102].”
BackgroundDerivation of Human Midbrain-Specific Organoids from Neuroepithelial Stem Cells
Monzel, A. S., Smits, L. M., Hemmer, K., Hachi, S., Moreno, E. L., van Wuellen, T., Jarazo, J., Walter, J., Brüggemann, I., Boussaad, I., et al. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.03.010 · Cited by 435
Vatansever, S., Schlessinger, A., Wacker, D., Kaniskan, H. Ü., Jin, J., Zhou, M., & Zhang, B. (2021) · Medicinal Research Reviews · doi:10.1002/med.21764 · Cited by 429
Drug candidates in clinical trials for Alzheimer’s disease
Hung, S.-Y., & Fu, W.-M. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0355-7 · Cited by 420
“Over two hundred compounds have reached Phase II clinical trials since 2003, but no new drugs have been approved for the treatment of AD [4, 10].”
BackgroundPound, P., & Ritskes-Hoitinga, M. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1678-1 · Cited by 419
The amyloid cascade hypothesis: are we poised for success or failure?
Karran, E., & De Strooper, B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13632 · Cited by 402
Modifiable pathways in Alzheimer’s disease: Mendelian randomisation analysis
Larsson, S. C., Traylor, M., Malik, R., Dichgans, M., Burgess, S., & Markus, H. S. (2017) · BMJ · doi:10.1136/bmj.j5375 · Cited by 382
The Platform Trial: An Efficient Strategy for Evaluating Multiple Treatments
Berry, S. M., Connor, J. T., & Lewis, R. J. (2015) · JAMA · doi:10.1001/jama.2015.2316 · Cited by 377
Bittner, T., Zetterberg, H., Teunissen, C. E., Ostlund, R. E., Militello, M., Andreasson, U., Hubeek, I., Gibson, D., Chu, D. C., Eichenlaub, U., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.09.009 · Cited by 374
“Disease-modifying treatments (DMTs) for AD are in development but none are yet available [1] because of the high attrition rate observed in clinical trials [3].”
Hampel, H., Mesulam, M.-M., Cuello, A. C., Khachaturian, A. S., Vergallo, A., Farlow, M. R., Snyder, P. J., Giacobini, E., & Khachaturian, Z. S. (2019) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2018.43 · Cited by 369
“Success rates among AD drugs in clinical development are disappointing low (34, 35), much lower than for cancer and other complex diseases.”
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease
Salloway, S., Farlow, M., McDade, E., Clifford, D. B., Wang, G., Llibre-Guerra, J. J., Hitchcock, J. M., Mills, S. L., Santacruz, A. M., Aschenbrenner, A. J., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01369-8 · Cited by 359
Likelihood of Null Effects of Large NHLBI Clinical Trials Has Increased over Time
Kaplan, R. M., & Irvin, V. L. (2015) · PLOS ONE · doi:10.1371/journal.pone.0132382 · Cited by 356
Metal Ions in Alzheimer’s Disease: A Key Role or Not?
Liu, Y., Nguyen, M., Robert, A., & Meunier, B. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00248 · Cited by 353
Koenig, A. M., Mechanic-Hamilton, D., Xie, S. X., Combs, M. F., Cappola, A. R., Xie, L., Detre, J. A., Wolk, D. A., & Arnold, S. E. (2017) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000202 · Cited by 350
Heavy Metals Exposure and Alzheimer’s Disease and Related Dementias
Bakulski, K. M., Seo, Y. A., Hickman, R. C., Brandt, D., Vadari, H. S., Hu, H., & Park, S. K. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-200282 · Cited by 345
“Despite urgent need and tremendous research efforts, pharmacological trials for AD have struggled [5].”
Calcium signaling and molecular mechanisms underlying neurodegenerative diseases
Pchitskaya, E., Popugaeva, E., & Bezprozvanny, I. (2018) · Cell Calcium · doi:10.1016/j.ceca.2017.06.008 · Cited by 349
“However, so far these agents did not show benefit in AD clinical trials (Cummings et al., 2014; Karran and Hardy, 2014; Karran et al., 2011).”
BackgroundElfawy, H. A., & Das, B. (2019) · Life Sciences · doi:10.1016/j.lfs.2018.12.029 · Cited by 343
New Insights Into the Pathogenesis of Alzheimer's Disease
Fan, L., Mao, C., Hu, X., Zhang, S., Yang, Z., Hu, Z., Sun, H., Fan, Y., Dong, Y., Yang, J., et al. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2019.01312 · Cited by 344
Cognitive training for people with mild to moderate dementia
Bahar-Fuchs, A., Martyr, A., Goh, A. M., Sabates, J., & Clare, L. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013069.pub2 · Cited by 342
Alzheimer’s disease, dementia, and stem cell therapy
Duncan, T., & Valenzuela, M. (2017) · Stem Cell Research & Therapy · doi:10.1186/s13287-017-0567-5 · Cited by 338
“Indeed, researchers have effectively treated AD in transgenic mouse models in more than 50 different ways [47].”
Implications of peptide assemblies in amyloid diseases
Ke, P. C., Sani, M.-A., Ding, F., Kakinen, A., Javed, I., Separovic, F., Davis, T. P., & Mezzenga, R. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00372b · Cited by 338
Addressing Dementia: The OECD Response
OECD (2015) · OECD Health Policy Studies · doi:10.1787/9789264231726-en · Cited by 327
Oblak, A. L., Lin, P. B., Kotredes, K. P., Pandey, R. S., Garceau, D., Williams, H. M., Uyar, A., O’Rourke, R., O’Rourke, S., Ingraham, C., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.713726 · Cited by 325
Solving neurodegeneration: common mechanisms and strategies for new treatments
Wareham, L. K., Liddelow, S. A., Temple, S., Benowitz, L. I., Di Polo, A., Wellington, C., Goldberg, J. L., He, Z., Duan, X., Bu, G., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00524-0 · Cited by 324
Guzior, N., Wi.eckowska, A., Panek, D., & Malawska, B. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666141106122628 · Cited by 323
“[232] showed that during the period between 2002 and 2012 there were 413 AD clinical trials performed and only”
BackgroundPrions, prionoids and protein misfolding disorders
Scheckel, C., & Aguzzi, A. (2018) · Nature Reviews Genetics · doi:10.1038/s41576-018-0011-4 · Cited by 321
Rosenberg, A., Mangialasche, F., Ngandu, T., Solomon, A., & Kivipelto, M. (2020) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2019.41 · Cited by 316
“Disease-modifying therapies are not yet available for AD, and despite the recent positive signals in some of the ongoing randomized controlled trials (RCTs) testing anti-amyloid compounds, drug trials have mostly reported disappointing results (3,4).”
BackgroundDrugs in Clinical Trials for Alzheimer's Disease: The Major Trends
Bachurin, S. O., Bovina, E. V., & Ustyugov, A. A. (2017) · Medicinal Research Reviews · doi:10.1002/med.21434 · Cited by 304
Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes
Cummings, J. (2018) · Clinical and Translational Science · doi:10.1111/cts.12491 · Cited by 298
Self-citationIn vitro Models of Neurodegenerative Diseases
Slanzi, A., Iannoto, G., Rossi, B., Zenaro, E., & Constantin, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00328 · Cited by 290
“…targeting neurodegenerative diseases has raised doubts about the translatability of animal disease models to human patients, creating a demand for better research tools in this field (Olanow et al., 2008; Cummings et al., 2014; Schneider et al., 2014; Pfeuffer et al., 2016; Anderson et al., 2017).”
BackgroundComputational Modeling of β-Secretase 1 (BACE-1) Inhibitors Using Ligand Based Approaches
Subramanian, G., Ramsundar, B., Pande, V., & Denny, R. A. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00290 · Cited by 285
Astrocyte senescence: Evidence and significance
Cohen, J., & Torres, C. (2019) · Aging Cell · doi:10.1111/acel.12937 · Cited by 281
Pohl, F., & Kong Thoo Lin, P. (2018) · Molecules · doi:10.3390/molecules23123283 · Cited by 272
“No new AD drugs have been approved by the Food and Drug Administration (FDA) since 2003 [8].”
BackgroundGiovinazzo, D., Bursac, B., Sbodio, J. I., Nalluru, S., Vignane, T., Snowman, A. M., Albacarys, L. M., Sedlak, T. W., Torregrossa, R., Whiteman, M., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2017225118 · Cited by 270
Centeno, E. G. Z., Cimarosti, H., & Bithell, A. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0258-4 · Cited by 268
“Reasons for this low success rate include the difficulty in identifying disease aetiology, the gap in translation between animal and human studies and a lack of appropriate human models to determine underlying mechanisms of action and for pre-clinical testing [5].”
Application of Metabolomics in Alzheimer’s Disease
Wilkins, J. M., & Trushina, E. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2017.00719 · Cited by 268
The biological pathways of Alzheimer disease: a review
Calabrò, M., Department of Biomedical and Dental Sciences and Morphofunctional Imaging, U. O. M., Rinaldi, C., Santoro, G., & Crisafulli, C. (2021) · AIMS Neuroscience · doi:10.3934/neuroscience.2021005 · Cited by 265
“6% of drug candidates targeting amyloid pathways, including β secretase inhibitors, γ secretase inhibitors, and Aβ itself, do not have a significant therapeutic effect on AD subjects [9].”
BackgroundCheung, C. Y., Ran, A. R., Wang, S., Chan, V. T. T., Sham, K., Hilal, S., Venketasubramanian, N., Cheng, C.-Y., Sabanayagam, C., Tham, Y. C., et al. (2022) · The Lancet Digital Health · doi:10.1016/s2589-7500(22)00169-8 · Cited by 264
A natural experiment on the effect of herpes zoster vaccination on dementia
Eyting, M., Xie, M., Michalik, F., Heß, S., Chung, S., & Geldsetzer, P. (2025) · Nature · doi:10.1038/s41586-025-08800-x · Cited by 238
Pistollato, F., Iglesias, R. C., Ruiz, R., Aparicio, S., Crespo, J., Lopez, L. D., Manna, P. P., Giampieri, F., & Battino, M. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.03.012 · Cited by 247
Cummings, J. (2023) · Drugs · doi:10.1007/s40265-023-01858-9 · Cited by 241
“Of the many negative trials, Aβ was a common target but accounted for a minority of all trials [22].”
BackgroundSelf-citationNutrition for the ageing brain: Towards evidence for an optimal diet
Vauzour, D., Camprubi-Robles, M., Miquel-Kergoat, S., Andres-Lacueva, C., Bánáti, D., Barberger-Gateau, P., Bowman, G. L., Caberlotto, L., Clarke, R., Hogervorst, E., et al. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2016.09.010 · Cited by 241
“sive worldwide research effort which has been overshadowed by the failure of over a hundred putative treatments (Becker et al., 2008; Cummings et al., 2014; Mullard, 2012).”
The “rights” of precision drug development for Alzheimer’s disease
Cummings, J., Feldman, H. H., & Scheltens, P. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0529-5 · Cited by 238
Self-citationEide, P. K., & Ringstad, G. (2019) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x18760974 · Cited by 234
Kiriiri, G. K., Njogu, P. M., & Mwangi, A. N. (2020) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-020-00047-9 · Cited by 227
“ease, immunological disorders, the human immunodeficiency virus-associated acquired immune deficiency syndrome (HIV-AIDs) [9], neglected tropical diseases (NTDs), and rare diseases [10].”
BackgroundWhy do so many clinical trials of therapies for Alzheimer's disease fail?
Anderson, R. M., Hadjichrysanthou, C., Evans, S., & Wong, M. M. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32399-1 · Cited by 228
New approaches to symptomatic treatments for Alzheimer’s disease
Cummings, J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00424-9 · Cited by 226
Self-citationHabchi, J., Chia, S., Limbocker, R., Mannini, B., Ahn, M., Perni, M., Hansson, O., Arosio, P., Kumita, J. R., Challa, P. K., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1615613114 · Cited by 223
“Although targeting Aβ accumulation has been pursued as a major potential therapeutic strategy against AD (14–17), no compound selected for this purpose has yet entered clinical use (18, 19).”
BackgroundXiao, S., Chan, P., Wang, T., Hong, Z., Wang, S., Kuang, W., He, J., Pan, X., Zhou, Y., Ji, Y., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00795-7 · Cited by 224
“Approximately 50% of the participants in the trial were carriers of the APOE4 gene and therefore had a higher likelihood of amyloid-related disease than noncarriers[5, 32].”
BackgroundSelf-citationCardiovascular disease models: A game changing paradigm in drug discovery and screening
Savoji, H., Mohammadi, M. H., Rafatian, N., Toroghi, M. K., Wang, E. Y., Zhao, Y., Korolj, A., Ahadian, S., & Radisic, M. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.09.036 · Cited by 223
Garner, J. P. (2014) · ILAR Journal · doi:10.1093/ilar/ilu047 · Cited by 221
Poor Translatability of Biomedical Research Using Animals — A Narrative Review
Marshall, L. J., Bailey, J., Cassotta, M., Herrmann, K., & Pistollato, F. (2023) · Alternatives to Laboratory Animals · doi:10.1177/02611929231157756 · Cited by 219
Combination Drug Therapy for the Management of Alzheimer’s Disease
Kabir, M. T., Uddin, M. S., Mamun, A. A., Jeandet, P., Aleya, L., Mansouri, R. A., Ashraf, G. M., Mathew, B., Bin-Jumah, M. N., & Abdel-Daim, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093272 · Cited by 217
Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function
Spiteri, A. G., Wishart, C. L., Pamphlett, R., Locatelli, G., & King, N. J. C. (2022) · Acta Neuropathologica · doi:10.1007/s00401-021-02384-2 · Cited by 244
The role of the immune system in Alzheimer disease: Etiology and treatment
Jevtic, S., Sengar, A. S., Salter, M. W., & McLaurin, J. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.08.005 · Cited by 215
“For decades, therapies have been developed that directly target Aβ production or aggregation, however, all have failed to slow disease progression (Cummings et al., 2014).”
BackgroundNarayanaswami, V., Dahl, K., Bernard-Gauthier, V., Josephson, L., Cumming, P., & Vasdev, N. (2018) · Molecular Imaging · doi:10.1177/1536012118792317 · Cited by 213
“Taking as an example the case of AD, over 200 compounds have reached phase II clinical trials for AD since 2003, but no new drugs have been approved.(256,257) Nevertheless, important lessons have been learned from failures of anti-AD therapies in late-stage clinical trials, including dimebon (Medivation and Pfizer) an…”
BackgroundReview of Current Strategies for Delivering Alzheimer’s Disease Drugs across the Blood-Brain Barrier
Wong, K. H., Riaz, M. K., Xie, Y., Zhang, X., Liu, Q., Chen, H., Bian, Z., Chen, X., Lu, A., & Yang, Z. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020381 · Cited by 213
“In some cases, trials employing small molecules or those using immunotherapies were not able to show significant difference between drug and placebo; some revealed unpredictable toxicity [5].”
ResultFemminella, G. D., Frangou, E., Love, S. B., Busza, G., Holmes, C., Ritchie, C., Lawrence, R., McFarlane, B., Tadros, G., Ridha, B. H., et al. (2019) · Trials · doi:10.1186/s13063-019-3259-x · Cited by 213
Festoff, B. W., Sajja, R. K., van Dreden, P., & Cucullo, L. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0670-z · Cited by 214
“Background Despite overarching evidence, the amyloid hypothesis in Alzheimer’s disease (AD) first elaborated in 1991, has yet to provide positive outcomes notwithstanding the billions spent on clinical trials [1].”
Neth, B. J., Mintz, A., Whitlow, C., Jung, Y., Solingapuram Sai, K., Register, T. C., Kellar, D., Lockhart, S. N., Hoscheidt, S., Maldjian, J., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.09.015 · Cited by 211
“With no established disease-modifying therapeutic or preventative strategy (Cummings et al., 2014), we must continue to explore unconventional interventions to combat this devastating disorder.”
BackgroundRobert, A., Liu, Y., Nguyen, M., & Meunier, B. (2015) · Accounts of Chemical Research · doi:10.1021/acs.accounts.5b00119 · Cited by 212
Morris, G. P., Clark, I. A., & Vissel, B. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1918-8 · Cited by 212
“The amyloid hypothesis has clearly held sway over the direction of interventional clinical trials [179] but this approach has so far proven unsuccessful [57, 136].”
BackgroundGao, X.-L., Sui, Y., Liu, S., & Sun, Y.-P. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.255995 · Cited by 211
“…34.4061 2016 2017 ▂▃▃▂▂ PRINCE M, WORLD ALZHEIMER REPO (Prince, 2015) 2015 31.5408 2017 2019 ▂▂▃▃▃ SCHELTENS P, LANCET (Scheltens et al., 2016) 2016 50.9821 2017 2019 ▂▂▃▃▃ CUMMINGS JL, ALZHEIMERS RES THER (Cummings et al., 2014) 2014 28.8266 2017 2019 ▂▂▃▃▃ SELKOE DJ, EMBO MOL MED (Selkoe and…”
InfluentialHabchi, J., Arosio, P., Perni, M., Costa, A. R., Yagi-Utsumi, M., Joshi, P., Chia, S., Cohen, S. I. A., Müller, M. B. D., Linse, S., et al. (2016) · Science Advances · doi:10.1126/sciadv.1501244 · Cited by 208
Weuve, J., Bennett, E. E., Ranker, L., Gianattasio, K. Z., Pedde, M., Adar, S. D., Yanosky, J. D., & Power, M. C. (2021) · Environmental Health Perspectives · doi:10.1289/ehp8716 · Cited by 209
“E ff orts to develop drugs to treat Alzheimer ’ s dementia (AD) have a >99 % failure rate (Cummings et al. 2014).”
High-Throughput Screening Platforms in the Discovery of Novel Drugs for Neurodegenerative Diseases
Aldewachi, H., Al-Zidan, R. N., Conner, M. T., & Salman, M. M. (2021) · Bioengineering · doi:10.3390/bioengineering8020030 · Cited by 207
“The failure rate of clinical trials for new treatments targeting NDDs, for example AD, is exceptionally high and usually exceeds 99% [71].”
Role of reactive oxygen species in the progression of Alzheimer’s disease
Bhatt, S., Puli, L., & Patil, C. R. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2020.12.004 · Cited by 207
Amyloid clearance defect in ApoE4 astrocytes is reversed by epigenetic correction of endosomal pH
Prasad, H., & Rao, R. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1801612115 · Cited by 207
“6%) in the clinic suggest that by the time amyloid plaques, neurofibrillary tangles, and neuronal death are detected, it is unlikely that disease progression can be halted and reversed (51).”
BackgroundFang, J., Zhang, P., Zhou, Y., Chiang, C.-W., Tan, J., Hou, Y., Stauffer, S., Li, L., Pieper, A. A., Cummings, J., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00138-z · Cited by 206
Self-citationHölscher, C. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.040 · Cited by 198
“Hölscher) symptom modifying drugs reaching the market (Cummings et al., 2014).”
BackgroundCauses and Patterns of Dementia: An Update in the Era of Redefining Alzheimer's Disease
James, B. D., & Bennett, D. A. (2019) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-040218-043758 · Cited by 199
Challenges for Alzheimer's Disease Therapy: Insights from Novel Mechanisms Beyond Memory Defects
Frozza, R. L., Lourenco, M. V., & De Felice, F. G. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00037 · Cited by 198
“These constraints may be due to that clinical trials have predominantly focused on therapies based on anti-amyloid strategies, since the amyloid cascade hypothesis has been placed at the center of therapeutic prospection (Karran et al., 2011; Cummings et al., 2014; Hendrix et al., 2016).”
BackgroundMild Behavioral Impairment as a Marker of Cognitive Decline in Cognitively Normal Older Adults
Creese, B., Brooker, H., Ismail, Z., Wesnes, K. A., Hampshire, A., Khan, Z., Megalogeni, M., Corbett, A., Aarsland, D., & Ballard, C. (2019) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.01.215 · Cited by 196
“0001), attentional fluctuation (F(2,8578)=10.”
BackgroundInfluential
Metadata
- Authors
- Cummings, J. L., Morstorf, T., & Zhong, K.
- Affiliations
- Cleveland Clinic (US)
- Touro University Nevada (US)
- Corresponding author
- Cummings, Jeffrey L
- Venue
- Alzheimer's Research & Therapy
- Published
- 2014-07-03
- Volume
- 6
- Issue
- 4
- Pages
- 37-37
- ISSN
- 1758-9193 (ISSN-L)
- PMC
- PMC4095696
- OpenAlex
- W2146249493
- Cited by
- 1,744
- References
- 29
- Citations by year
- 2026: 86 · 2025: 65 · 2024: 113 · 2023: 122 · 2022: 189 · 2021: 193 · 2020: 208 · 2019: 207 · 2018: 200 · 2017: 144 · 2016: 122 · 2015: 79 · 2014: 15
- FWCI
- 79.49
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Alzheimer s Research & Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, drug development pipeline, clinical trials, trial attrition, disease-modifying therapy, immunotherapy, cholinesterase inhibitors, NMDA receptor antagonists, ClinicalTrials.gov, pharmaceutical industry sponsorship
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
